



# **AN EVOLUTION**

THE STORY OF THE MILTON PARK LIFE SCIENCES CLUSTER

## Foreword

By The Rt Hon. the Lord Heseltine CH

When I was asked to write the foreword to this book I was reminded of my visit to Milton Park in 1993 for the opening of the Business Development Centre. MEPC's decision to invest in buildings for biotech companies was bold, but having read the stories in this book, it has been a worthwhile endeavour for all concerned and has helped to make this location the thriving business community that it is today, hosting 50 life science companies and half-a-million square feet of laboratory space.

It is a testament to the courage of the entrepreneurs who have grown the cluster that they include amongst their achievements not only the raising of many hundreds of millions of pounds of investment, but the invention and commercialisation of therapeutic drugs, diagnostic and medical device technologies, that contribute to better healthcare for all.

The sector continues to be a pillar of strength in the UK economy and has remained robust in the face of recession. This fact attests to the inherent quality of life sciences on both the academic and

industrial fronts across the whole of Britain: across the Golden Triangle centres of Oxford, London and Cambridge, as well as in Nottingham and Manchester and also in South Wales and Scotland.

We must not however rest on past achievements but press forward with determination to fulfil the vision as laid out in the government's recent *Strategy for UK Life Sciences*. In particular we must ensure a proper integration of local government with the "triple helix" – academia, industry and clinical research bases and the NHS.

There is an exciting future at Milton Park, and through initiatives such as the Science Vale UK Enterprise Zones and the Local Development Order, I am delighted to see that the government and public sector are facilitating growth and enabling investment in future success and job creation.





## CONTENTS

<b>Introduction</b>	<b>1</b>
<b>Perspective</b>	<b>3</b>
<b>Growth studies</b>	
<b>Evotec</b>	<b>7</b>
<b>Green Biologics</b>	<b>9</b>
<b>Amgen/BioVex</b>	<b>11</b>
<b>Vertex Pharmaceuticals</b>	<b>13</b>
<b>Oxford Immunotec</b>	<b>15</b>
<b>ResMed</b>	<b>17</b>
<b>Oxford BioTherapeutics</b>	<b>19</b>
<b>Immunocore</b>	<b>21</b>
<b>Oxitec</b>	<b>23</b>
<b>PsiOxus Therapeutics</b>	<b>25</b>
<b>An eye to the future</b>	<b>27</b>
<b>Timeline</b>	<b>29</b>

## Introduction

### The Milton Park Life Sciences Cluster

Milton Park is one of the largest mixed-use business estates in Europe and is home to a wide range of companies leading the way in the high-tech, innovative, R&D industries. This book is a record and celebration of the growth and vibrancy of the life sciences cluster at the heart of Milton Park, the largest in Oxfordshire and indeed one of the most significant in the UK.

It illustrates the development of the park over time and, in a series of growth studies, highlights ten of the many successful companies that have contributed to the evolution of the cluster. The material for the studies is drawn from interviews with senior personnel and provides an insight into the key events and the exciting research and development taking place at their companies. The cluster has a high proportion of companies developing new medicines, however there is also exemplary work going on in a range of fields including medical and green technologies.

The cluster continues to expand, now hosting nearly fifty life science companies, spread across biotechnology, medical devices, contract and clinical research services and associated industries and has reached a critical mass as a location for the life sciences industry. The growth of Milton Park has been and will continue to be strengthened by the proximity of many academic institutions and internationally renowned centres of excellence based in the Science Vale UK area and Oxfordshire.

MEPC foresees a continued expansion of the UK life sciences sector and is committed to playing its part in this success story by providing the best environment for enterprises of all sizes in this dynamic field.

We hope that you will find the following pages informative and inspiring.



# Perspective

## Nick Cross and Ian Laing: Milton Park visionaries

Few of the 6,500 people arriving daily on Milton Park realise their jobs, the first-class facilities and beautiful parkland exist here thanks to the vision of two men, Nick Cross and Ian Laing.

Business partners and friends, the pair met in 1965 when Oxford University undergraduates. By 1979, Ian was Managing Director of the English Property Company (EPC), one of the UK's largest developers, which had bought the Milton Trading Estate, a near derelict former military depot, eight years earlier to develop as a warehousing site. MEPC acquired EPC in 1985 and, as Milton Park was less attractive to investment institutions than the City of London office developments, Ian saw the opportunity that a cash generative asset presented in the right hands. He persuaded Nick to return from the US to join him in a new venture and together they oversaw a transformation of the site including new roads and landscaping.

Simultaneously, the changing environment was presenting new possibilities and challenges. The completed UK motorway system enhanced Didcot's pre-eminence as a transport and warehousing hub for the South of England. However revised planning laws removed the site's restriction to warehousing alone. Nick and Ian realised that Milton Park's unique location, close to the largest concentration of research and development in Western Europe, was its key asset. With this in mind they invited Martin Wood, founder of Oxford Instruments, and John Harwood, chief executive of Oxfordshire County Council, to a strategy meeting. An hour later, the die was cast. One-third of

Milton Park would be devoted to a variety of properties tailor-made for science-based companies at various stages in their life cycles.

Nick and Ian became ever more interested in the scientific companies attracted to the Park. Selling their shareholdings in Milton Park to MEPC, they turned their attention to finding technology-based and life science companies to invest in. By 1999, they had helped to establish Oxford Asymmetry (now part of Evotec AG), Oxford Semiconductor, Oxagen and Doctors.net. Since then they have invested in and provided a great deal of management time to a total of thirteen science-based businesses, all bar two of which have been based at Milton Park.



(L-R) Nick Cross and Ian Laing



Milton Park 1960's



Milton Park 2013



"Evotec has become arguably the largest employer of chemists in the UK."

The merger of Milton Park-based Oxford Asymmetry International (OAI) with Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) in the year 2000 created a world leader in the discovery and development of novel small molecule drugs. OAI was then a chemistry centric business with aspirations to focus on drug discovery: Evotec supplied the needed biological expertise. Evotec now focuses on a systematic, comprehensive and unbiased technology platform to drive drug discovery.

The first bioscience company on Milton Park, OAI moved into two starter units in 1991. Within five years, it had expanded into two more buildings containing a GMP-compliant pilot plant and development chemistry facilities. Discovery chemistry remained in the starter units. Following a successful London Stock Exchange listing in 1998 which raised £20 million, OAI took on another three

buildings to house bespoke chemical discovery and development facilities. By the mid 2000's, now merged with Evotec, the company was one of the major scientific tenants on the Park, employing nearly 400 people. Although headcount dipped consequent to the sale of the development business to Aptuit in 2007, Evotec has become arguably the largest employer of chemists in the UK. Evotec now employs around 250 people, the majority medicinal chemists, at Milton Park. This equates to nearly 40% of the group's global workforce.



Dr Mario Polywka, OAI's founding chemist, now Evotec's Chief Operating Officer



German Head Office  
and operations in  
US, UK and India

**€534m**

Market capitalisation:  
€534 m (28.10.13)



UK's largest  
employers  
of chemists



Work with  
18 of world's top 20  
pharmaceutical  
companies





"Green Biologics has gone through various stages of growth and expansion. Today, Milton Park has been able to meet our needs. I'm confident they will be able to do the same in the future as we look to expand or research and development activities."

Green Biologics Ltd (GBL) is a world-leader in the production of renewable *n*-butanol from the microbial fermentation of sugars from sustainable feedstocks. With a \$6 billion annual market value, *n*-butanol is widely used by the chemical industry to manufacture a variety of everyday household items.

GBL arrived and took up residence at one end of 45 Milton Park, then a large warehouse. Laboratories were created using second-hand benches and equipment and within three years, the company had expanded to fill most of the building.

Technical development, improving microbial strains and optimising the fermentation process, has always been GBL's main activity. Several customers in China have licensed GBL's microbial technology, enabling validation at commercial scale, and also production from a challenging cellulosic feedstock based on maize residues. The supply chain has now been fully tested by the production, shipping and sale of over 50 tons of biobutanol in the US.



World-leaders  
in *n*-biobutanol  
production



Operations in the  
US, China, India  
and Brazil



Successful capital  
light business model

£25m

Raised; £15 million  
in late 2013



Dr Edward Green, Founder and Chief Scientific Advisor





“Milton Park has the cachet of an Oxford address, important for a biotech company wanting to make its way in the world.”

The decision by BioVex management to use a large chunk of early funding to move to Milton Park in 2001 was a brave gamble that paid off. “We created custom facilities for our mix of research and development (R&D) where we have been able to work safely, grow and adapt as the company has progressed,” says Dr Colin Love, Vice President R&D Operations.

BioVex spun out from University College London to develop genetically modified viruses able to kill cancer cells, but sparing normal tissue. The company grew quickly, becoming a US entity in 2005, in part to improve access to funding. Much of the business – clinical trials, regulatory affairs, manufacturing - moved to Woburn MA, leaving process and analytical development in the UK. By 2010, nearly \$120 million had been raised to bring the lead product, a potential therapy for late-stage malignant melanoma, to the final stages of clinical

development. The company was then employing about 120 people, 25-30 in the UK and the rest in the US. At this point, BioVex was acquired by Amgen (NASDAQ: AMGN), the world’s largest independent biotech company, for a headline figure of \$1 billion.

There are now 40 people at Milton Park, the majority providing quality control and global release testing services for clinical supplies of the oncolytic virus, manufactured in the US.

“Milton Park has the cachet of an Oxford address, important for a biotech company wanting to make its way in the world. The location of the site, particularly in relation to trains and buses, has helped recruitment. Compared to a university science park, Milton Park benefits from having a mix of companies, not just science-based. This is good for the health of the park.”



Leaders in  
development of  
oncolytic virus  
vaccines


**\$120m**  
Raised \$120 million  
to take lead product  
to final stage of  
clinical trials



Wholly-owned  
subsidiary of Amgen



Provide quality control  
and global release  
testing services for  
virus supplies





"Although most of the research is into new medicines to treat cancer, their scientists are making progress in understanding inflammatory diseases of the brain for which medicine currently has no answer."

Vertex Pharmaceuticals Inc is engaged in discovery, development and commercialisation of new medicines to treat life-threatening or modifying diseases including cystic fibrosis, rheumatoid arthritis and hepatitis C and influenza. In addition to these clinical programmes, Vertex has more than a dozen ongoing preclinical programmes.

Founded nearly 25 years ago in Cambridge, MA, Vertex today has approximately 1,800 people working at research and development (R&D) sites and commercial offices in the US, Europe, Canada and Australia.

Milton Park hosts Vertex's first international R&D site. Established in 1998, an initial team of 15 has grown to about 150 people, two-thirds scientists, focused primarily on preclinical research. Clinical operations and data management groups support European study sites participating in company sponsored clinical programmes. A large financial group supports many of Vertex's European subsidiaries.



Two FDA approved products

**\$1.53bn**  
2012 total revenues  
of \$1.53 billion



Listed shares  
(NASDAQ: VRTX)



Over 1,800  
employees  
worldwide



Dr Julian Golec,  
Vice President Research and Site  
Head, Europe





"It's a global business, growing organically, with offices in Boston (2007), Memphis (2011) and Tokyo (2012)."

Oxford Immunotec came to Milton Park, looking for facilities appropriate for a company nearing European approval of its first product, the T-SPOT®.TB test, a novel diagnostic test detecting tuberculosis infection. That was nearly ten years ago. Starting off sub-leasing space, they've moved twice to larger facilities. Now, as their manufacturing programme expands, a third site on the Park is planned.

It's a global business, growing organically, with offices in Boston (2007), Memphis (2011) and Tokyo (2012). Forty of the company's 150 employees work at Milton Park, engaged in corporate activities, sales and marketing, technical support activities for all the ex-US business (Europe, Far East, Africa and South America), research and development, clinical studies and regulatory affairs are also managed out of Oxford, along with all manufacturing and a small service laboratory. Sales of the T-SPOT.TB test are growing rapidly.



Novel TB diagnostic test approved in 50 countries

**\$110m**

\$110 million venture capital investment

**£13.4m**

£13.4 million sales (2012): >60% growth over past 3 years



Ranked 49 in Sunday Times 2013 Tech Track 100



# ResMed

“Recognised as global leaders in developing, manufacturing and marketing medical devices to treat sleep and breathing disorders.”

ResMed UK, a subsidiary of a US parent company, has been on Milton Park for the last 18 years. Recognised a global leader in developing, manufacturing and marketing medical devices to treat sleep and breathing disorders, the core technology was developed as a collaboration with the University of Sydney.

The European sales and marketing operation on Milton Park has grown from 10 to nearly 60 people. Aside from marketing and commercial roles, Milton Park employees provide customer services, warehousing, and finance and IT support for other European subsidiaries.

ResMed's first product was a therapy for obstructive sleep apnoea in which the upper airway collapses many times during sleep, causing the patient to snore or temporarily stop breathing, resulting in chronically disturbed sleep and a range of

health complications. ResMed's bedside device, connected via a small nasal or face mask worn by the sleeper, monitors breathing, gently delivering pressurised air to restore regular breathing patterns. This device is now part of a comprehensive range of products for management of sleep-disordered breathing. More recently ResMed has introduced a device to treat central sleep apnoea, a condition mainly associated with heart failure in which the brain fails to instruct the lungs to breathe.

Working with the British Lung Foundation, ResMed is raising awareness of breathing disorders and undertreatment. A London clinic was opened to provide diagnostic and treatment services to complement those provided through the NHS. Patients now come to ResMed's treatment rooms on Milton Park where clinicians may customise devices and help patients choose the most suitable masks or nasal delivery devices.



Ross Sommerville, Vice President  
UK and European Partner Network



Europe contributes  
c.40% total sales

**\$1.5bn**  
2012 group sales  
c.\$1.5 billion



Shares listed:  
NYSE:RMD and  
ASX: RMD.AX



Global leaders  
in treating  
sleep disorders



# OXFORD BioTherapeutics

Oxford BioTherapeutics (OBT) set out determined to establish itself as an international biotechnology player. The initial focus was on leveraging its unique database – one of the world's largest proprietary collections of disease-associated proteins – to identify novel oncology drug targets. This valuable discovery technology enabled the company to strike transforming partnerships with major players including US West Coast companies Amgen, Medarex (now part of Bristol Myers) and Seattle Genetics. Through its collaborations, OBT has assembled the component technologies now embodied in its pipeline of antibody-drug conjugates (ADC's) to treat cancer, which are advancing to clinical studies in a \$1 billion investment alliance with Menarini.

Started nine years ago in Milton Park with ten people, the company has grown to employ about 50, two-thirds in OBT's base in San Jose, CA. Drug



Developing novel antibody drug conjugates to treat cancer



Proprietary OGAP® technology is one of world's largest cancer targeting systems



Major partners include Amgen, Medarex, Seattle Genetics, Sanofi, BioWa, Boehringer Ingelheim

"New technologies are driving a renaissance in the cancer field, and selecting the right therapeutic target is fundamental for the development of successful treatments."



Dr Christian Rohlff,  
Chief Executive Officer

\$1bn

\$1 billion oncology investment collaboration with Menarini



## IMMUNOCORE

targeting T cell receptors

“2013 was a milestone year for Immunocore, signing multi-programme deals with Genentech, a member of the Roche Group, and GSK.”

Immunocore is an expert in exploiting the immune system to fight cancer, infectious and autoimmune diseases. Its novel T cell receptor (TCR) technology was spun out of Oxford University into a company called Avidex which came to Milton Park in 2000. Avidex was acquired by German company MediGene AG in 2006 then bought back two years later to form Immunocore. A sister company, Adaptimmune, was established independently to develop T cell adoptive therapy from the same technology platform and is co-located with Immunocore on Milton Park.

Immunocore’s lead product candidate has just finished a phase I/II dose-finding clinical study in patients with late-stage malignant melanoma. Adaptimmune is testing the efficacy of two TCR’s in eight clinical studies against diseases including HIV and a range of cancers.

2013 was a milestone year for Immunocore, signing multi-programme deals with Genentech, a member

of the Roche Group, and GSK. Each programme is worth potentially in excess of \$320 million excluding royalties. Their success was acknowledged by OBN with the award of the 2013 Best Biotech Dealmaker and by their recognition as one of the industry’s most promising private biotechnology companies in Fierce Biotech’s 2013 Fierce 15.

In common with other pre-revenue bioscience companies on the Park, Immunocore and Adaptimmune have offices and laboratories in two of the less modern buildings. As the companies expanded, MEPC contributed towards equipping a third, newer building. Immunocore and Adaptimmune together employ around 100 people with a further seven managing US clinical studies in Philadelphia, PA.



James Noble,  
Chief Executive Officer.



Experts in T Cell  
Receptor engineering

£75m  
£75 million  
funding raised



Multi-programme deals  
with Genentech and GSK



Five TCRs in ten  
clinical studies  
(Immunocore and  
Adaptimmune)





OXITEC

“Oxitec is the first and only company in the world to use genetically sterile insects to control the spread of human and plant diseases.”

Oxitec is the first and only company in the world to use genetically sterile insects to control the insects that spread diseases and damage crops. Their pioneering approach is environmentally-friendly and sustainable, avoiding the damaging side effects of insecticides and the development of resistance.

Spun out from Oxford University in 2002, the company set about developing its first commercial product to control the mosquitoes that spread the dengue fever virus. Affecting over 300 million people annually, there are neither effective vaccines nor medications against this virus. The only way to control the disease is to control the mosquito which spreads the disease. Company scientists on Milton Park genetically engineered the reversibly-sterile mosquito strains and developed breeding processes. Production is carried out in the affected countries. Field studies in Brazil have shown almost complete suppression of the wild dengue mosquito after six months periodic release of the sterile males. The company hopes

that marketing approval will be received for a commercial launch in Brazil before the end of 2014.

Oxitec has now turned its attention to the olive fly, a cause of massive crop losses from olive trees, to demonstrate the value of its approach in controlling agricultural pests. If approved, their study will be the first outdoor trial of a genetically modified insect in the EU.

The company's unique technology requires an unusual mix of facilities. They solved the problem on Milton Park by leasing three buildings, one for offices and molecular biology laboratories, a second for creating new mosquito strains and a third breeding facility.

In its lifetime, Oxitec has raised about £18 million through a mix of family offices and venture capital to fund its growth. A truly international company, a quarter of its 40 UK employees now come from overseas. There are also staff in Malaysia and Brazil.



Engineering insects  
to control disease

£18m

Raised £18 million  
funding over 10 years



Planning EU's first  
trial of genetically  
modified insects



First product to  
control deadly  
dengue virus





"PsiOxus has established collaborations with pharmaceutical giant Bayer Schering, the US military and four international universities."

PsiOxus Therapeutics, one of Milton Park's newer tenants, is the product of a 2011 strategic merger between two spin-out companies, one from Oxford University and the other from Imperial College London, creating a single entity with a critical mass of science and funding.

Following a successful funding round grossing £22 million, twelve employees moved with the company from Cherwell Innovation Centre in North Oxfordshire to 154 Milton Park. Previously an empty shell, the building was designed and fitted out by MEPC to suit PsiOxus's office and laboratory requirements. Two years later, the building houses 22 employees, the majority with PhD's.

PsiOxus has established collaborations with pharmaceutical giant Bayer Schering, the US military and four international universities. European and Asian clinical studies for two programmes are managed from Milton Park. The most advanced

clinical programme completed a phase 2 study to treat the wasting disease of cancer at the end of 2013. The oncolytic viral programme has started safety studies in patients with colorectal and ovarian cancers. One of two pre-clinical programmes is providing the next generation of oncolytic virus, selecting viruses that have lost the ability to grow in normal cells, but which rapidly kill certain types of cancers. The strategy is to arm these viruses and make them more efficient cancer killers as well as immune system stimulants so the body will fight back more strongly.



Dr John Beadle,  
Chief Executive Officer

PsiOxus see their location in Oxford as important for the company's growth. Close scientific collaborations, and a pipeline agreement, are in place with Oxford University. In seeking their new premises, several locations were considered. Milton Park was chosen primarily because the facilities could be built to the company's specification.



A focus on novel  
cancer therapeutics

£22m

£22 million  
funding raised  
over 3.5 years



Oncolytic viral  
programme partnered  
with Bayer Schering



Two clinical and  
two preclinical  
programmes



## An eye to the future

### A home for innovative companies

Milton Park is a unique place that has witnessed an extraordinary journey from providing only low grade storage space to now offering the highest quality world-class laboratories that meet the needs of a considerable variety of businesses however small or large.

The site is central to the Oxfordshire science cluster and its growth has been fuelled by the ecosystem that delivers expertise and skills to trigger truly revolutionary research in the journey to commercial success and healthcare benefits. The constituents of this community have been brought together by the foresighted management team over a long period of time based on an unwavering commitment to investment by MEPC through the economic cycles.

The endeavours in this book highlight a small selection of advancements in scientific discovery which have anchored an environment where

entrepreneurs, scientists and investors have thrived, and Milton Park has provided the canvas on which these great events have been painted.

I have played a small part in this progression and the future success of the estate is well set but requires the continuing support of all the players who must recognise that it is private enterprise that has created the engine of innovation to power the local economy and make it the pride of Oxfordshire. We are now on the threshold of further evolution as ever assisted by all our partners in the public sector. Milton Park will continue to provide a home for innovation to grow, succeed and belong.

Finally we are very grateful to the individuals who have shared their companies' experiences with us and also to OBN (formerly Oxfordshire Bioscience Network) for preparing this publication and conducting the interviews.



James Dipple, Managing Director



## TIMELINE

1971

Milton Park depot is sold by MOD at auction for £625,000

1990

Ian Laing and Nick Cross establish strategy for science-based companies

1993

Lord Heseltine opens Business Development Centre (BDC) for start-up and early stage companies

1998

Vertex Pharmaceuticals sets up UK HQ at 88 Milton Park  
Park Club Health Centre and Fitness Centre opens for 4,000 employees across estate

2000

Immunocore progenitor, Avidex spins out from Oxford University and arrives as tenant  
OAI merges with Evotec

2002

MEPC opens Business Campus II which today is home to, *inter alia*, Chroma Therapeutics, Karus Therapeutics and Carbosynth

2004

Central 127 opens  
Oxford BioTherapeutics established  
Oxitec sets up on the Park  
Oxford Immunotec arrives  
Duke of York visits Evotec and Cozart (now Alere Toxicology)

2008

Lord Drayson opens new Innovation Centre  
Vertex expands

2011

PsiOxus arrives  
Vertex Pharmaceuticals launch Incivek®  
Amgen acquires BioVex in £1bn deal  
Enterprise Zone status awarded

2013

Green Biologics acquires US plant  
Oxford Immunotec NASDAQ listing  
Immunocore signs GSK and Genentech deals  
Oxitec successful Moscamed field trial  
ResMed announces record Q3 earnings

1985

MEPC acquires EPC, the owner of Milton Trading Estate, renamed as Milton Park

1991

Oxford University spin-out Oxford Asymmetry International (OAI) arrives as first bioscience company

1997

New 75,000 sq. ft. R&D facility announced for OAI, Oxagen and Prolifix move to BDC

1999

Park Centre opens providing shops and more facilities  
Park Centre offices launched

2001

BioVex arrives  
Business Campus II announced with HQ for Oxford Glycosciences (later acquired by Celltech/UCB)

2003

ResMed sets up in Milton Park  
Green Biologics moves in

2007

Aptuit purchases chemical development business from Evotec  
OBN moves in  
Concateno purchases Cozart  
SRA acquires Constella Group  
Serentis acquires Surface Therapeutics

2010

Building 100 opens with Sunguard and Aptiv Solutions  
Hybrid Systems/ Myotec Therapeutics merge to form PsiOxus Therapeutics

2012

Oxford BioTherapeutics Menarini deal  
PsiOxus £22m funding  
Local development order approved

2014

Buildings 101 and 102 open  
Milton Park reaches 6,800 employees and 2.5m sq. ft. with over 220 companies




**people&the park**

a Royal first: HRH Prince Andrew visits the park

**HRH Prince Andrew** has visited the Park for the first time since it opened in 2001. The Prince was given a guided tour of the Park by the Chairman of the Park's Management Committee, Sir David Tredinnick, and was shown around the business park's facilities and its surrounding environment. The Prince also met with local business leaders and officials, and was given a tour of the Park's facilities and its surrounding environment.

**HRH Prince Andrew** has visited the Park for the first time since it opened in 2001. The Prince was given a guided tour of the Park by the Chairman of the Park's Management Committee, Sir David Tredinnick, and was shown around the business park's facilities and its surrounding environment. The Prince also met with local business leaders and officials, and was given a tour of the Park's facilities and its surrounding environment.



**TB diagnostic company raises £7 million**

Orion Immunotec has raised £7m for the worldwide sale of its revolutionary test for diagnosing tuberculosis.

Orion Immunotec, based in Abingdon, Oxfordshire, has raised £7m for the worldwide sale of its revolutionary test for diagnosing tuberculosis. The company, which has developed a test that can detect TB in just 15 minutes, has secured its first major international deal with the US-based pharmaceutical company, Novartis. The deal, worth \$100m, will see Novartis sell the test in the US and Canada, and Orion Immunotec will receive a further \$100m if the test proves successful in other markets.

**Lost again?**

Not for long!

**Welcome the Vegital!**

**Leading edge**

**Key to a place in the sun**

**Open and shut case**

**CONSTRUCTION IN**

**M**

**25**

**Park Life**

Success breeds success here...

**T**he success of Milton Park is highly regarded as a benchmark for business parks across the globe. The Park's unique blend of business, leisure and residential facilities has created a vibrant community where people live, work and play. The Park's success is reflected in its impressive list of tenants, including major international companies such as Google, Microsoft, and Oracle, as well as smaller, innovative start-ups. The Park's commitment to sustainability and environmental responsibility is evident in its green spaces, recycling facilities, and energy-efficient buildings. The Park's proximity to the M40 motorway and the A404 road provides easy access to the rest of the UK and Europe. The Park's excellent infrastructure, including its own railway station, makes it a hub for business travel. The Park's vibrant social scene includes a range of amenities such as restaurants, bars, and clubs, as well as a dedicated sports and leisure complex. The Park's success is built on a foundation of strong relationships between businesses, employees, and the local community. The Park's future looks bright, with continued investment in infrastructure and facilities, and a focus on innovation and growth.

**Milton Park means business**



**MILTON UPDATE**

News from Milton Park - Abingdon, Oxfordshire

**SUMMER 1995 ISSUE NUMBER 2**

**MICHAEL HESELTINE** IN ACTION AT THE OFFICIAL OPENING OF THE BUSINESS DEVELOPMENT CENTRE

see inside for full story

**GROW. SUCCEED. BELONG**





Credits: Concept and Delivery by OBN. Architectural Photography by Quintin Lake. Writing by BioValue. Designed by Studio Moko. © 2014 All rights reserved.